Page last updated: 2024-10-26

fendiline and Carcinoma, Ductal, Pancreatic

fendiline has been researched along with Carcinoma, Ductal, Pancreatic in 1 studies

Fendiline: Coronary vasodilator; inhibits calcium function in muscle cells in excitation-contraction coupling; proposed as antiarrhythmic and antianginal agents.

Research Excerpts

ExcerptRelevanceReference
"As fendiline has been approved for treatment of patients with angina, we hypothesized that, if proven effective, combinatorial therapies using this agent would be easily translatable to clinic for testing in PDAC patients."1.51Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC. ( Alhothali, M; Chellappan, S; Iyer, G; Lawrence, HR; Mathew, M; Padmanabhan, J; Yang, S, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alhothali, M1
Mathew, M1
Iyer, G1
Lawrence, HR1
Yang, S1
Chellappan, S1
Padmanabhan, J1

Other Studies

1 other study available for fendiline and Carcinoma, Ductal, Pancreatic

ArticleYear
Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
    International journal of molecular sciences, 2019, May-16, Volume: 20, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot

2019